PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY INDICATION • Market segmentation by indication • Comparison by indication • Osteosarcoma - Market size and forecast 2018-2023 • Ewing's sarcoma - Market size and forecast 2018-2023 • Chondrosarcoma - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by indication PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amgen • Bayer AG • Bristol-Myers Squibb Company • Merck & Co. Inc. • Pfizer Inc. PART 15: APPENDIX • Research methodology • List of abbreviations • Definition of vendors classification PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global bone cancer drugs market pipeline: Overview Exhibit 18: Global bone cancer drugs market pipeline: Snapshot Exhibit 19: Indication - Market share 2018-2023 (%) Exhibit 20: Comparison by indication Exhibit 21: Osteosarcoma - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Osteosarcoma - Year-over-year growth 2019-2023 (%) Exhibit 23: Ewing's sarcoma - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Ewing's sarcoma - Year-over-year growth 2019-2023 (%) Exhibit 25: Chondrosarcoma - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Chondrosarcoma - Year-over-year growth 2019-2023 (%) Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Others - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by indication Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Asia - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 43: ROW - Year-over-year growth 2019-2023 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Impact of drivers and challenges Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: Amgen - Vendor overview Exhibit 54: Amgen - Business segments Exhibit 55: Amgen - Organizational developments Exhibit 56: Amgen - Geographic focus Exhibit 57: Amgen - Key offerings Exhibit 58: Amgen - Key customers Exhibit 59: Bayer AG - Vendor overview Exhibit 60: Bayer AG - Business segments Exhibit 61: Bayer AG - Organizational developments Exhibit 62: Bayer AG - Geographic focus Exhibit 63: Bayer AG - Segment focus Exhibit 64: Bayer AG - Key offerings Exhibit 65: Bayer AG - Key customers Exhibit 66: Bristol-Myers Squibb Company - Vendor overview Exhibit 67: Bristol-Myers Squibb Company - Business segments Exhibit 68: Bristol-Myers Squibb Company - Organizational developments Exhibit 69: Bristol-Myers Squibb Company - Geographic focus Exhibit 70: Bristol-Myers Squibb Company - Key offerings Exhibit 71: Bristol-Myers Squibb Company - Key customers Exhibit 72: Merck & Co. Inc. - Vendor overview Exhibit 73: Merck & Co. Inc. - Business segments Exhibit 74: Merck & Co. Inc. - Organizational developments Exhibit 75: Merck & Co. Inc. - Geographic focus Exhibit 76: Merck & Co. Inc. - Segment focus Exhibit 77: Merck & Co. Inc. - Key offerings Exhibit 78: Merck & Co. Inc. - Key customers Exhibit 79: Pfizer Inc. - Vendor overview Exhibit 80: Pfizer Inc. - Business segments Exhibit 81: Pfizer Inc. - Organizational developments Exhibit 82: Pfizer Inc. - Geographic focus Exhibit 83: Pfizer Inc. - Segment focus Exhibit 84: Pfizer Inc. - Key offerings Exhibit 85: Pfizer Inc. - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of vendors classification

Amgen Bayer AG Bristol-Myers Squibb Company Merck & Co. Inc. Pfizer Inc.